Compound ID | 1874
Synonym(s): NXL104 | AVE1330A
Class: Beta-lactamase inhibitor
| Agent Type: | Synthetic; Small molecule; Direct acting; Antibiotic adjuvant; |
| Mechanism of action: | Binds reversibly to the beta-lactamase in the active site; inhibits class A, C, D beta-lactamases |
| Combined with other compounds: | Yes |
| Description: | Synthetic compound. 2015 approved in fixed combination with ceftazidime. Orally available prodrug in clinical development, fixed combination with aztreonam in clinical development; a non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane (DBO); no intrinsic antibacterial activity |
| Institute where first reported: | Sanofi-Aventis, Novexel, AstraZeneca, Pfizer, Abbvie (formerly Actavis, Allergan, Forest Laboratories) |
| Year first mentioned: | 2002 |
| Highest development stage: | Approved by FDA in 2015 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/9835049 |
| Guide to Pharmacology: | avibactam |
| Citations: |
|